Johnson & Johnson vs Sibanye Stillwater Ltd — how do they compare? Johnson & Johnson trades at $261.41 (market cap $618.09B), while Sibanye Stillwater Ltd trades at $10 (market cap $6.88B). The key difference: Johnson & Johnson is far larger — about 89.8× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays the higher dividend (8.17%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Sibanye Stillwater Ltd for 51 Days on average.
| JNJ | SBSW | |
|---|---|---|
Market Cap | $618.09B | $6.88B |
Volume | 6,050,983 | 4,474,536 |
Sector | Health | Basic Materials |
52-Week High | $278.43 | $21.12 |
52-Week Low | $186.00 | $8.00 |
Typical Hold Time | 129 Days | 51 Days |
Enterprise Value | $646.37B | $7.78B |
Dividend Yield | 2.09% | 8.17% |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
SBSW trades at $10.00, up 3.31% with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company shows strong revenue growth to $129.68B in 2025 and improved cash flow, though net income remains negative. Analyst consensus is moderately bullish with a $14.25 price target, supported by recent institutional buying activity and positive coverage of H1 2026 results.
The outlook suggests potential upside based on valuation metrics (P/E 8.12, P/S 0.7) and projected 2026 profitability, but risks include persistent negative earnings, high debt levels, and commodity price sensitivity. Investors should weigh the attractive valuation against operational execution challenges in the mining sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →